Celularity Inc. Fair Value Adjustment of Warrants
Celularity Inc. (CELU) reported Fair Value Adjustment of Warrants of $3.32 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-04-30
- Celularity Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$1.98M.
- Celularity Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $4.26M.
- Celularity Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was $1.28M.
- Celularity Inc. fair value adjustment of warrants for the quarter ending 2025-03-31 was -$242.00K, a 102.73% decline year-over-year.
- Celularity Inc. fair value adjustment of warrants for fiscal 2025 was $3.32M.
- Celularity Inc. fair value adjustment of warrants for fiscal 2024 was -$398.00K.
- Celularity Inc. fair value adjustment of warrants for fiscal 2023 was -$6.16M.
- Celularity Inc. fair value adjustment of warrants for fiscal 2022 was -$42.11M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $2.28M derived: sum of 2 quarters · filed 2026-04-30 | $3.56M derived: sum of 3 quarters · filed 2026-04-30 | $3.32M 10-K · filed 2026-04-30 | |||
| 2025-09-30 | $4.26M 10-Q · filed 2025-11-14 | $5.54M derived: sum of 2 quarters · filed 2025-11-14 | $5.30M 10-Q · filed 2025-11-14 | $3.74M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2025-06-30 | $1.28M 10-Q · filed 2025-08-29 | $1.03M 10-Q · filed 2025-08-29 | -$520.00K derived: sum of 3 quarters · filed 2026-04-30 | -$1.23M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2025-03-31 | -$242.00K 10-Q · filed 2025-08-29 | -$1.80M derived: sum of 2 quarters · filed 2026-04-30 | -$2.51M derived: sum of 3 quarters · filed 2026-04-30 | -$9.52M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$2.27M derived: sum of 2 quarters · filed 2026-04-30 | -$9.27M derived: sum of 3 quarters · filed 2026-04-30 | -$398.00K 10-K · filed 2026-04-30 | |||
| 2024-09-30 | -$714.00K 10-Q · filed 2025-11-14 | -$7.72M derived: sum of 2 quarters · filed 2025-11-14 | $1.16M 10-Q · filed 2025-11-14 | $1.78M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$7.00M 10-Q · filed 2025-08-29 | $1.87M 10-Q · filed 2025-08-29 | $2.49M derived: sum of 3 quarters · filed 2025-08-29 | -$2.69M derived: sum of 4 quarters · filed 2025-08-29 | |||
| 2024-03-31 | $8.88M 10-Q · filed 2025-08-29 | $9.50M derived: sum of 2 quarters · filed 2025-08-29 | $4.31M derived: sum of 3 quarters · filed 2025-08-29 | $4.45M derived: sum of 4 quarters · filed 2025-08-29 | |||
| 2023-12-31 | $624.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$4.56M derived: sum of 2 quarters · filed 2025-05-08 | -$4.43M derived: sum of 3 quarters · filed 2025-05-08 | -$6.16M 10-K · filed 2025-05-08 | |||
| 2023-09-30 | -$5.19M 10-Q · filed 2024-12-06 | -$5.05M derived: sum of 2 quarters · filed 2024-12-06 | -$6.79M 10-Q · filed 2024-12-06 | -$17.28M derived: sum of 4 quarters · filed 2024-12-06 | |||
| 2023-06-30 | $134.00K 10-Q · filed 2024-11-07 | -$1.60M 10-Q · filed 2024-11-07 | -$12.10M derived: sum of 3 quarters · filed 2024-11-07 | -$21.43M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-03-31 | -$1.74M 10-Q · filed 2024-10-16 | -$12.23M derived: sum of 2 quarters · filed 2024-10-16 | -$21.56M derived: sum of 3 quarters · filed 2024-10-16 | -$64.78M derived: sum of 4 quarters · filed 2024-10-16 | |||
| 2022-12-31 | -$10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$19.83M derived: sum of 2 quarters · filed 2024-07-30 | -$63.04M derived: sum of 3 quarters · filed 2024-07-30 | -$42.11M 10-K · filed 2024-07-30 | |||
| 2022-09-30 | -$9.33M 10-Q · filed 2024-01-03 | -$52.55M derived: sum of 2 quarters · filed 2024-01-03 | -$31.61M 10-Q · filed 2024-01-03 | -$42.84M derived: sum of 4 quarters · filed 2024-01-03 | |||
| 2022-06-30 | -$43.21M 10-Q · filed 2023-08-14 | -$22.28M 10-Q · filed 2023-08-14 | -$33.50M derived: sum of 3 quarters · filed 2023-08-14 | -$73.44M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $20.93M 10-Q · filed 2023-05-22 | $9.71M derived: sum of 2 quarters · filed 2023-05-22 | -$30.23M derived: sum of 3 quarters · filed 2023-05-22 | -$29.05M derived: sum of 4 quarters · filed 2023-05-22 | |||
| 2021-12-31 | -$11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$51.16M derived: sum of 2 quarters · filed 2023-03-31 | -$49.99M derived: sum of 3 quarters · filed 2023-03-31 | -$13.48M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$39.94M 10-Q · filed 2022-11-10 | -$38.76M derived: sum of 2 quarters · filed 2022-11-10 | -$2.26M 10-Q · filed 2022-11-10 | $4.36M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $1.17M 10-Q · filed 2022-08-09 | $5.56M 10-Q · filed 2021-08-19 | $37.68M 10-Q · filed 2022-08-09 | -$34.45M 10-Q · filed 2021-08-19 | $44.30M derived: sum of 3 quarters · filed 2022-08-09 | $89.74M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $36.51M 10-Q · filed 2022-05-16 | -$40.01M 10-Q · filed 2021-05-24 | $43.13M derived: sum of 2 quarters · filed 2022-05-16 | $88.57M derived: sum of 3 quarters · filed 2022-05-16 | $100.53M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $6.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $52.06M derived: sum of 2 quarters · filed 2022-03-31 | $64.03M derived: sum of 3 quarters · filed 2022-03-31 | $58.69M 10-K · filed 2022-03-31 | $46.63M 10-K/A · filed 2021-05-24 | ||
| 2020-09-30 | $45.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $57.41M derived: sum of 2 quarters · filed 2021-11-12 | $52.06M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $11.97M 10-Q · filed 2021-08-19 | $6.62M 10-Q · filed 2021-08-19 | |||||
| 2020-03-31 | -$5.34M 10-Q · filed 2021-05-24 | ||||||
| 2019-12-31 | -$4.49M 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |